{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:36:18Z","timestamp":1768678578626,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Italian administrative healthcare databases are frequently used for studies on real-world drug utilization. However, there is currently a lack of evidence on the accuracy of administrative data in describing the use of infusive antineoplastics. In this study, we used rituximab as a case study to investigate the validity of the regional administrative healthcare database of Tuscany (RAD) in describing the utilization of infusive antineoplastics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified patients aged 18 years or older who had received \u22651 rituximab administration between 2011 and 2014 in the onco-haematology ward of the University Hospital of Siena. We retrieved this information from the Hospital Pharmacy Database (HPD-UHS) and linked the person-level information to RAD. Patients who had received \u22651dispensing of rituximab, single administration episodes, and patients treated for non-Hodgkin Lymphoma (nHL) or Chronic Lymphocytic Leukemia (CLL) were identified in RAD and validated using HPD-UHS as the reference standard. We identified the indications of use using algorithms based on diagnostic codes (ICD9CM codes, nHL=200*, 202*; CLL=204.1). We tested 22 algorithms of different complexity for each indication of use and calculated sensitivity and positive predictive value (PPV), with 95% confidence intervals (95%CI), as measures of validity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to HPD-UHS, 307 patients received rituximab for nHL (N=174), CLL (N=21), or other unspecified indications (N=112) in the onco-haematology ward of the University Hospital of Siena. We identified 295 rituximab users in RAD (sensitivity=96.1%), but PPV could not be assessed due to missing information in RAD on dispensing hospital wards. We identified individual rituximab administration episodes with sensitivity=78.6% [95%CI: 76.4-80.6] and PPV=87.6% [95%CI: 86.1-89.2]. Sensitivity of algorithms tested for identifying nHL and CLL ranged from 87.7% to 91.9% for nHL and from 52.4% to 82.7% for CLL. PPV ranged from 64.7% to 66.1% for nHL and from 32.4% to 37.5% for CLL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings suggest that RAD is a very sensitive source of information for identifying patients who received rituximab for onco-haematological indications. Single administration episodes were identified with good-to-high accuracy. Patients receiving rituximab for nHL were identified with high sensitivity and acceptable PPV, while the validity for CLL was suboptimal.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1059109","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:18:05Z","timestamp":1685510285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications"],"prefix":"10.3389","volume":"13","author":[{"given":"Claudia","family":"Bartolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Moscatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Spini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Barchielli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Donnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Ziche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2476","article-title":"From inception to ConcePTION: genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeeding","volume":"111","author":"Thurin","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2411-y","article-title":"NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro\/cardiovascular disease","volume":"74","author":"Roberto","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0600-0","article-title":"Adherence of elderly patients with cardiovascular disease to statins and the risk of exacerbation of chronic obstructive pulmonary disease: evidence from an Italian real-world investigation","volume":"35","author":"Rea","year":"2018","journal-title":"Drugs Aging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00095","article-title":"Pattern of use of biosimilar and originator somatropin in Italy: a population-based multiple databases study during the years 2009-2014","volume":"9","author":"Marcian\u00f2","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414550419","article-title":"Triptan use in Italy: insights from administrative databases [published correction appears in cephalalgia","volume":"35","author":"Da Cas","year":"2015","journal-title":"Cephalalgia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229973","article-title":"Real word evidence on rituximab utilization: combining administrative and hospital-pharmacy data","volume":"15","author":"Roberto","year":"2020","journal-title":"PloS One"},{"key":"B7","unstructured":"Istat census2010"},{"key":"B8","article-title":"Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy","volume":"2","author":"Corrao","year":"2008","journal-title":"Biomed Stat Clin Epidemiol"},{"key":"B9","unstructured":"Linfoma non-Hodgkin2018"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-8020-7","article-title":"Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks","volume":"34","author":"Sailler","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.555","article-title":"Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the patient alert card","volume":"8","author":"Sarsour","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.7.832","article-title":"Indications for rituximab use in an integrated health care delivery system","volume":"26","author":"Delate","year":"2020","journal-title":"J Managed Care Specialty Pharm JMCP"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5606\/ArchRheumatol.2014.3855","article-title":"The off-label use of rituximab for the management of inflammatory disorders","volume":"29","author":"Moukadem","year":"2014","journal-title":"Am Univ Beirut Med Center Exp"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2012-000074.260","article-title":"Off-label use of rituximab in a general hospitalEuropean journal of hospital pharmacy","volume":"19","author":"Garcia","year":"2012","journal-title":"Sci Pract"},{"key":"B15","unstructured":""},{"key":"B16","article-title":"Validation of algorithms in studies based on routinely collected health data: general principles","author":"Ehrenstein","year":"2021","journal-title":"7 Eric I Benchimol"},{"key":"B17","first-page":"10","volume-title":"Confidence intervals","author":"Sullivan","year":"2017"},{"key":"B18","volume-title":"Stata statistical software: release 14","year":"2015"},{"key":"B19","volume-title":"Prevalence","author":"Tenny","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5083","article-title":"Time-related biases in pharmacoepidemiology","volume":"29","author":"Suissa","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1504","article-title":"Assessing cancer treatment information using Medicare and hospital discharge data among women with non-Hodgkin lymphoma in a Los Angeles county case-control study","volume":"29","author":"Zhong","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31824e342f","article-title":"Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens","volume":"52","author":"Lamont","year":"2014","journal-title":"Med Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji189","article-title":"Criterion validity of Medicare chemotherapy claims in cancer and leukemia group b breast and lung cancer trial participants","volume":"97","author":"Lamont","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/EDE.0000000000001208","article-title":"Validity of antineoplastic procedure codes in the Danish national patient registry: the case of colorectal cancer","volume":"31","author":"Broe","year":"2020","journal-title":"Epidemiology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5256","article-title":"Validation of an electronic algorithm for Hodgkin and non-Hodgkin lymphoma in ICD-10-CM","volume":"30","author":"Epstein","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B26","first-page":"18","article-title":"Positive predictive value of an algorithm used for cancer surveillance in the U.S","volume":"26","author":"Webber","year":"2019","journal-title":"Armed Forces. MSMR."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31824def85","article-title":"Validation of electronic data on chemotherapy and hormone therapy use in HMOs","volume":"51","author":"Ritzwoller","year":"2013","journal-title":"Med Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5263","article-title":"Validity of claims-based algorithms for selected cancers in Japan: results from the VALIDATE-J study","volume":"30","author":"de Luise","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160648","article-title":"Identifying cases of type 2 diabetes in heterogeneous data sources: strategy from the EMIF project","volume":"11","author":"Roberto","year":"2016","journal-title":"PloS One"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1059109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:18:12Z","timestamp":1685510292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1059109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":29,"alternative-id":["10.3389\/fonc.2023.1059109"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1059109","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"1059109"}}